Academic Journal
GLP-1 receptor agonist medications for weight loss: Sociodemographic patterns of awareness, use, and access in a U.S. national cohort.
| Τίτλος: | GLP-1 receptor agonist medications for weight loss: Sociodemographic patterns of awareness, use, and access in a U.S. national cohort. |
|---|---|
| Συγγραφείς: | Sanborn J; Institute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, NY, United States; Department of Epidemiology & Biostatistics, Graduate School of Public Health and Health Policy, The City University of New York, New York, NY, USA. Electronic address: jenna.sanborn@sph.cuny.edu., Fleary SA; Institute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, NY, United States; Department of Community Health and Social Sciences, Graduate School of Public Health and Health Policy, The City University of New York, New York, USA., Nash D; Institute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, NY, United States; Department of Epidemiology & Biostatistics, Graduate School of Public Health and Health Policy, The City University of New York, New York, NY, USA., Penrose K; Institute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, NY, United States., Parcesepe AM; University of North Carolina at Chapel Hill Gillings School of Public Health and Carolina Population Center, Chapel Hill, NC, USA., Piltch-Loeb R; Institute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, NY, United States; Department of Environmental Occupational Geospatial Health, Graduate School of Public Health and Health Policy, The City University of New York, New York, USA., Nuñez J; Institute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, NY, United States., Shen Y; Institute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, NY, United States., Robertson MM; Institute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, NY, United States; Department of Epidemiology & Biostatistics, Graduate School of Public Health and Health Policy, The City University of New York, New York, NY, USA. |
| Πηγή: | Annals of epidemiology [Ann Epidemiol] 2026 Oct; Vol. 122, pp. 110151. Date of Electronic Publication: 2026 Jun 25. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Elsevier Country of Publication: United States NLM ID: 9100013 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2585 (Electronic) Linking ISSN: 10472797 NLM ISO Abbreviation: Ann Epidemiol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: New York, NY : Elsevier, c1990- |
| Ιατρικοί όροι (MeSH): | Weight Loss*/drug effects , Health Services Accessibility*/statistics & numerical data , Obesity*/drug therapy , Glucagon-Like Peptide-1 Receptor Agonists* , Health Knowledge, Attitudes, Practice*, United States/epidemiology ; Humans ; Female ; Male ; Middle Aged ; Adult ; Cohort Studies ; Aged ; Sociodemographic Factors ; Glucagon-Like Peptide-1 Receptor ; Socioeconomic Factors ; Young Adult |
| Περίληψη: | Purpose: To describe patterns of glucagon-like peptide-1 receptor agonist (GLP1-RA) medication awareness, use, and access in a US adult cohort. Methods: Using self-reported December 2023 data from a nationwide cohort (N = 4555), we examined predictors of awareness, use (≤3 years), and inability to access GLP1-RA medications. Poisson regression with robust standard errors estimated age/sex-adjusted prevalence ratios. Analyses were conducted overall and among participants meeting FDA clinical-eligibility criteria (BMI ≥30 kg/m² or ≥27 kg/m² + ≥1 comorbidity; N = 1883). Results: Awareness was 81.6%; use was 8.3% overall, 13.4% among clinically-eligible participants, and 4.0% among ineligible participants. Overall, use was highest at ages 30-39 and 50-64 and among Hispanic and Black adults, parents, smokers, and those with healthcare barriers. Among clinically-eligible participants, use was lower among men (aPR=0.76, 95% CI: 0.60-0.96) and those with healthcare access barriers (aPR=0.47 [0.35-0.63]), and higher among those with income ≥ $100,000 versus < $49,000 (aPR=1.49 [1.12-1.98]). Among those who attempted treatment, 49.9% were unsuccessful; inability was more common for those with healthcare barriers (aPR=1.42 [1.14-1.77]). Conclusions: GLP1-RA awareness is high, but predictors of uptake and access differ by eligibility. Sociodemographic factors predicted uptake in the full cohort; income, sex, and healthcare barriers were significant predictors among clinically-eligible adults. (Copyright © 2026 The Authors. Published by Elsevier Inc. All rights reserved.) |
| Competing Interests: | Declaration of Competing Interest The City University of New York (CUNY) School of Public Health received research support from Pfizer during the conduct of this study which was paid directly to CUNY, with Dr. Nash serving as the Principal Investigator. |
| References: | BMC Public Health. 2019 Aug 16;19(1):1122. (PMID: 31420029) Aesthet Surg J. 2023 Dec 14;44(1):60-67. (PMID: 37402640) Annu Rev Public Health. 2018 Apr 1;39:273-289. (PMID: 29328865) BMC Fam Pract. 2016 Mar 31;17:38. (PMID: 27036116) Drug Healthc Patient Saf. 2025 Apr 25;17:121-134. (PMID: 40302900) J Prim Care Community Health. 2024 Jan-Dec;15:21501319241303608. (PMID: 39644194) Gastroenterol Clin North Am. 2023 Jun;52(2):429-441. (PMID: 37197884) J Clin Med. 2024 Aug 09;13(16):. (PMID: 39200816) BMJ. 2024 Jul 23;386:q1645. (PMID: 39043396) Lancet Diabetes Endocrinol. 2016 Nov;4(11):913-921. (PMID: 27595918) Rand Health Q. 2025 Dec 16;13(1):3. (PMID: 41415116) Obes Res Clin Pract. 2017 May - Jun;11(3):352-359. (PMID: 27569863) Stroke. 2022 May;53(5):1813-1822. (PMID: 35259929) J Am Pharm Assoc (2003). 2024 Jan-Feb;64(1):133-138. (PMID: 37821008) Curr Psychiatry Rep. 2025 May;27(5):278-285. (PMID: 40100584) JAMA Health Forum. 2023 Apr 7;4(4):e230493. (PMID: 37083822) Surg Obes Relat Dis. 2020 Mar;16(3):414-419. (PMID: 31917198) BMC Prim Care. 2024 Aug 20;25(1):311. (PMID: 39164618) Emerg Infect Dis. 2022 Nov;28(11):2171-2180. (PMID: 36191624) BMJ Open. 2021 Sep 21;11(9):e048778. (PMID: 34548354) Am J Emerg Med. 2024 Apr;78:89-94. (PMID: 38241775) JAMA Netw Open. 2025 Jan 02;8(1):e2455222. (PMID: 39836425) |
| Grant Information: | P2C HD050924 United States HD NICHD NIH HHS; RF1 MH132360 United States MH NIMH NIH HHS; UH3 AI133675 United States AI NIAID NIH HHS |
| Contributed Indexing: | Keywords: And health knowledge; Attitudes; Cohort studies; Glucagon-like peptide 1 receptor agonists; Practice; Risk factors; Socioeconomic factors; United States |
| Substance Nomenclature: | 0 (Glucagon-Like Peptide-1 Receptor Agonists) 0 (Glucagon-Like Peptide-1 Receptor) |
| Entry Date(s): | Date Created: 20260625 Date Completed: 20260915 Latest Revision: 20260923 |
| Update Code: | 20260923 |
| PubMed Central ID: | PMC13401313 |
| DOI: | 10.1016/j.annepidem.2026.110151 |
| PMID: | 42349695 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1873-2585 |
|---|---|
| DOI: | 10.1016/j.annepidem.2026.110151 |